Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, D. C.
Right arrow Articles by Mori, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, D. C.
Right arrow Articles by Mori, T. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2377-2386, 2002
© 2002 by the American Diabetes Association, Inc.

Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia

Dick C. Chan1, Gerald F. Watts1, P. Hugh R. Barrett1, Lawrence J. Beilin1, Trevor G. Redgrave2, and Trevor A. Mori1

1 Department of Medicine, University of Western Australia and the Western Australian Institute for Medical Research, Crawley, Western Australia
2 Department of Physiology, University of Western Australia, Crawley, Western Australia

Hepatic accumulation of lipid substrates perturbs apolipoproteinB-100 (apoB) metabolism in insulin-resistant, obese subjects and may account for increased risk of cardiovascular disease. In a placebo-controlled trial, we examined the independent and combined effects of decreasing cholesterol synthesis with atorvastatin (40 mg/day) and triglyceride synthesis with fish oils (4 g/day) on apoB kinetics. The subjects were 48 viscerally obese, insulin-resistant men with dyslipidemia who were studied in a fasted state. We found that atorvastatin significantly decreased plasma apoB-containing lipoproteins (P < 0.001, main effect) through increases in the fractional catabolic rate (FCR) of VLDL-, IDL-, and LDL-apoB (P < 0.01). Fish oils significantly decreased plasma levels of triglycerides and VLDL-apoB (P < 0.001), decreased the VLDL-apoB secretion rate (P < 0.01), but increased the conversion of VLDL to LDL (P < 0.001). Compared with placebo, combined treatment with atorvastatin and fish oils decreased VLDL-apoB secretion (P < 0.03) and increased the FCR of apoB in each lipoprotein fraction (P < 0.03) and the percent conversion of VLDL to LDL (P < 0.05). None of the treatments altered insulin resistance. In conclusion, in visceral obesity, atorvastatin increased hepatic clearance of all apoB-containing lipoproteins, whereas fish oils decreased hepatic secretion of VLDL-apoB. The differential effects of atorvastatin and fish oils on apoB kinetics support their combined use in correcting defective apoB metabolism in obese, insulin-resistant subjects.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. M. McKenney and D. Sica
Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia
Am. J. Health Syst. Pharm., March 15, 2007; 64(6): 595 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
D. E. Telford, B. G. Sutherland, J. Y. Edwards, J. D. Andrews, P. H. R. Barrett, and M. W. Huff
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
J. Lipid Res., March 1, 2007; 48(3): 699 - 708.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. Ramakrishnan
Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments
J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
K. G. Parhofer and P. H. R. Barrett
Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies
J. Lipid Res., August 1, 2006; 47(8): 1620 - 1630.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
P. H. R. Barrett, D. C. Chan, and G. F. Watts
Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans
J. Lipid Res., August 1, 2006; 47(8): 1607 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. C Chan, G. F Watts, M. N Nguyen, and P H. R Barrett
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
Am. J. Clinical Nutrition, July 1, 2006; 84(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
Y. A Carpentier, L. Portois, and W. J Malaisse
n-3 Fatty acids and the metabolic syndrome
Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1499 - 1504S.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. N. Ginsberg
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Myerson, C. Ngai, J. Jones, S. Holleran, R. Ramakrishnan, L. Berglund, and H. N. Ginsberg
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia
J. Lipid Res., December 1, 2005; 46(12): 2735 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. E. Telford, S. M. Lipson, P. H. R. Barrett, B. G. Sutherland, J. Y. Edwards, J. D. Aebi, H. Dehmlow, O. H. Morand, and M. W. Huff
A Novel Inhibitor of Oxidosqualene:Lanosterol Cyclase Inhibits Very Low-Density Lipoprotein Apolipoprotein B100 (ApoB100) Production and Enhances Low-Density Lipoprotein ApoB100 Catabolism Through Marked Reduction in Hepatic Cholesterol Content
Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2608 - 2614.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
K. C. Maki, M. E. Van Elswyk, D. McCarthy, S. P. Hess, P. E. Veith, M. Bell, P. Subbaiah, and M. H. Davidson
Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol
J. Am. Coll. Nutr., June 1, 2005; 24(3): 189 - 199.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
J. Lipid Res., May 1, 2005; 46(5): 872 - 884.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. Bilz, S. Wagner, M. Schmitz, A. Bedynek, U. Keller, and T. Demant
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
J. Lipid Res., January 1, 2004; 45(1): 174 - 185.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
B. H. C. M. T. Prinsen, J. A. Romijn, P. H. Bisschop, M. M. J. de Barse, P. H. R. Barrett, M. Ackermans, R. Berger, T. J. Rabelink, and M. G. M. de Sain-van der Velden
Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans
J. Lipid Res., July 1, 2003; 44(7): 1341 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Ouguerram, T. Magot, Y. Zair, J. S. Marchini, B. Charbonnel, H. Laouenan, and M. Krempf
Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 332 - 337.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
K. G. Parhofer, E. Laubach, and P. H. R. Barrett
Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients
J. Lipid Res., June 1, 2003; 44(6): 1192 - 1198.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Diabetes, March 1, 2003; 52(3): 803 - 811.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.